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C L I N I C A L  E X P E R I E N C E
The diagnostic utility of clinical exome sequencing in 60 
patients with hearing loss disorders: A single- institution 
experience
1  | INTRODUC TION
Congenital ear anomalies and hearing impairment are often present 
in patients with underlying genetic disorders. Germline genomic vari-
ants are responsible for at least 50% of congenital and/or childhood- 
onset sensorineural hearing loss (SNHL). Furthermore, 20%– 60% of 
patients with bilateral microtia and congenital aural atresia may have 
an identifiable genetic syndrome.1
Standard diagnostic approaches involving single gene test-
ing and chromosomal microarrays have limited utility in diag-
nosing monogenic conditions with high degrees of genetic and 
phenotypic heterogeneity.2 Delay in confirming a genetic diag-
nosis can lead to incorrect diagnostic workup, uncertain progno-
sis, inadequate treatment, delayed referral to relevant medical 
subspecialties and lack of anticipation of potential additional 
comorbidities.
The development of next- generation DNA sequencing (NGS) 
has contributed significantly to the diagnosis, study and care of 
Mendelian monogenic disorders. The capacity to perform simulta-
neous sequencing of multiple genomic regions makes NGS partic-
ularly appropriate for the investigation of genetically and clinically 
heterogeneous conditions, such as hereditary hearing loss. NGS- 
based– targeted gene panels and exome sequencing have become 
increasingly available for monogenic disorders. Reported diagnostic 
rates range between 20% and 50%, depending upon the patient co-
hort and the chosen testing platform.3
Next- generation sequencing approaches can lead to molecu-
lar diagnoses which can inform clinical decision- making. Clinical 
exome sequencing (CES) is therefore increasingly being used 
for testing patients with congenital ear anomalies and hearing 
disorders.4– 6 As the clinical availability of NGS increases, there 
is a need to evaluate its impact in routine practice. This study 
reports experience with CES in 60 consecutive patients with 
congenital ear or hearing disorders with a suspected genetic ae-
tiology, to determine diagnostic yield and document the clinical 
implications.
2  | PATIENTS AND METHODS
We conducted a retrospective survey of clinical and molecular re-
sults from 60 consecutive patients with ear and hearing disorders, 
referred for proband- only clinical exome sequencing (CES) to the 
NHS North West Genomic Laboratory Hub. CES was performed 
for diagnostic purposes, with prior consent by the patients and/or 
their guardian(s). All patients were evaluated and referred for CES 
by a consultant clinical geneticist. CES experiments were con-
ducted using a custom- designed Agilent SureSelect XT Focused 
Exome capture library and the NextSeq 500 sequencer (Illumina, 
Inc). A phenotype- driven virtual gene panel was generated per 
patient, customised based on their clinical features, as described 
previously.7 Following bioinformatics analyses (supplemental 
material), the clinical significance of candidate variants was in-
terpreted independently by two registered Clinical Scientists as 
per the American College of Medical Genetics and Genomics and 
the Association for Molecular Pathology (ACMG- AMP) guide-
lines.8 These guidelines assign genomic variants identified into a 
five- tier system based on different types of evidence (population 
data, computational and predictive analysis, functional criteria 
and segregation data). As per these criteria, genomic variants are 
classified as pathogenic, likely pathogenic, variant of unknown 
significance, likely benign and benign.8 Where needed, cases were 
further reviewed at internal Multidisciplinary Team meetings or 
through internal communication between the consultant clinical 
geneticist and clinical scientists from the Rare Disease Clinical 
Exome team.
3  | E VALUATION OF CES DIAGNOSTIC 
UTILIT Y
A search was conducted in the internal referral database identify-
ing patients with phenotypes matching query terms (Table S1, sup-
plemental material) that indicated the presence of hearing loss and/
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or abnormalities of the external, middle or inner ear, either isolated 
or as part of their phenotype. Gender, age at referral, clinical fea-
tures, previous genetic testing, CES results and actions prompted 
after CES were obtained from available medical records, the labo-
ratory's internal database. Finally, to determine the diagnostic rate, 
CES results were categorised as follows: (1) confirmed, (2) possibly 
confirmed and (3) not confirmed (Table S2).
4  | RESULTS
4.1 | Cohort clinical characteristics
Seventy- eight per cent (47/60) of patients were under age 18 (median 
6, range 0– 73 years, 95% CI 7.51– 14.73). A 40:60 female: male ratio 
was observed. Twenty patients (33%) had apparently isolated sen-
sorineural hearing loss (19 bilateral and 1 unilateral SNHL). Twenty- 
seven patients (45%) had SNHL as part of a complex phenotype (25 
bilateral and 2 unilateral SNHL). Ten (17%) had a degree of microtia 
and/or atresia accompanied by other clinical features. Three (5%) 
were referred with mixed hearing loss with additional clinical fea-
tures, most commonly neurological or ophthalmic disorders (Table 1).
4.2 | Genetic investigations prior to CES
Thirty- six patients (60%) had some genetic testing prior to undergo-
ing CES (Table 2). No variants of clinical significance were reported 
in 32 patients (88%), and inconclusive findings were reported in the 
remaining four: two had chromosomal microarray variants of uncer-
tain significance (VUS), namely a balanced rearrangement of chro-
mosome 10 and a deletion on the X chromosome. Two patients had 
single heterozygous variants in GJB2; c.306G>C, p.(Lys102Asn) and 
c.101T>C, p.(Met34Thr), but no second GJB2 variant was found in 
trans in either patient, rendering these findings unlikely to account 
for their auditory phenotype.
4.3 | Variant spectrum and diagnostic yield
Forty distinct variants were identified in 24 genes (Table S3). Genes 
most frequently harbouring variants were SLC26A4, LOXHD1, 
CDH23 and CDH7. Eleven variants (27%) were novel at time of analy-
sis. Predicted loss- of- function and missense variants were reported 
in equal proportions (n = 13, respectively). Twenty- six variants (65%) 
were found as pathogenic or likely pathogenic and fourteen variants 
were classified as variants of uncertain significance (VUS) (35%) ac-
cording to ACMG guidelines.8
Clinical exome sequencing resulted in an overall diagnostic 
yield of 31% (19/60). This was higher in patients with sensorineural 
hearing loss: 60% (12/20) in the non- syndromic 22% (6/27) in the 
syndromic SNHL groups (Figure 1). Only one case with syndromic 
microtia- atresia, was categorised as “possibly confirmed”, with a ho-
mozygous class 3 variant in ORC6 (Meier- Gorlin syndrome type 3). 
Autosomal recessive inheritance underpins 85% of diagnoses in this 
cohort without a family history. Inconclusive findings were reported 
in 11 patients (18%): Seven presented with complex phenotypes 
Key points
• Genetic aetiologies are an important cause of congenital 
ear anomalies and hearing impairment.
• Next- generation sequencing (NGS) strategies, such as 
targeted gene panels or clinical exome sequencing (CES), 
are effective tools in the diagnosis of patients with in-
herited hearing impairment, with clear advantages over 
previous genetic testing approaches.
• Clinical exome sequencing in our cohort shows the ge-
netic heterogeneity of syndromic and non- syndromic 
congenital ear and hearing disorders, highlighting the 
clinical utility of undergoing genomic investigations.
• Multidisciplinary decision- making for diagnostic workup 
and management, including close collaboration between 
genetics, otolaryngology, audiology and other allied 
specialties, is key in the investigation of congenital ear 
and hearing disorders.
• Timely molecular genetic diagnosis can streamline pa-
tient care and potentially improve clinical outcomes.
TA B L E  1   Additional phenotypes in patients with syndromic 
SNHL and syndromic microtia- atresia (n = 41)
Category
No. of patients with 
reported abnormality (%)
Neurodevelopmental delay 16 (39%)
Ophthalmic disorders 14 (34%)
Central nervous system malformation 7 (17%)
Other neurological abnormalities 6 (15%)
Oral cleft 6 (15%)
Congenital cardiovascular defect 5 (12%)
Limb abnormalities 4 (10%)
Facial dysmorphology 3 (7%)
Skin disorder 3 (7%)





Upper aerodigestive tract abnormality 2 (5%)
Gastrointestinal abnormality 2 (5%)
Early- onset obesity 1 (2%)
Growth abnormality 1 (2%)
Abbreviation: SNHL, sensorineural hearing loss.
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including developmental delay, learning disability, myopathy and/or 
dual sensory impairment (Table S3). No plausibly pathogenic variants 
were identified in 30 patients (50%).
4.4 | CES directs clinical care
Clinical exome sequencing results directly informed clinical 
decision- making in 15 patients (25%). Five were referred for as-
sessment or reassessment by other specialists. One patient re-
ferred with non- syndromic SNHL, had a homozygous likely 
pathogenic variant in CDH23, prompting reassessment by oph-
thalmology to assess for any evidence of Usher syndrome. Two 
patients were referred to specialist multidisciplinary clinics for 
inherited cardiac anomalies and CHARGE syndrome respec-
tively. Two patients were referred back to audiology for further 
detailed phenotypic evaluation. In five cases, molecular findings 
prompted genetic investigations in similarly affected family mem-
bers. Results in a patient with bilateral SNHL and myopathy with a 
possible dual diagnosis involving CEP78 and ETFDH enabled test-
ing and early diagnosis in a similarly affected daughter. Another 
patient was found to be a carrier for Becker muscular dystrophy, 
which enabled cascade testing and clinical investigations for fam-
ily members. Finally, nine patients without confirmed diagnosis 
underwent whole genome sequencing as part of the 100 000 
Genomes Project.9
5  | DISCUSSION
The implementation of genomic sequencing approaches has demon-
strated diagnostic utility in the context of SNHL.10 Here, we report 
our experience with CES in a cohort of patients presenting with a 
variety of ear and hearing loss phenotypes. Our diagnostic rate of 
Genetic investigation No. of cases Clinical category
GJB2/GJB6 testing 19 Non- syndromic SNHL (n = 14)
Syndromic SNHL (n = 4)
Syndromic mixed HL (n = 1)
Chromosomal microarray 12 Syndromic SNHL (n = 9)
Syndromic microtia- atresia (n = 3)
Fragile X syndrome 3 Syndromic SNHL (n = 2)
Syndromic microtia- atresia (n = 1)
m.1555A>G 2 Syndromic SNHL (n = 1)
Non- syndromic SNHL (n = 1)
NGS gene panela  2 Syndromic SNHL (n = 2)
Specific single gene testingb  1 Syndromic SNHL (n = 1)
Abbreviations: NGS, next- generation sequencing; SNHL, sensorineural hearing loss.
aLeeds leukodystrophy and mitochondrial leukodystrophy panels; Newcastle panel of genes for 
complex I deficiency.
bSCA17 gene.
TA B L E  2   Genetic testing prior to CES
F I G U R E  1   Diagnostic rate of clinical 
exome sequencing (CES) per clinical 
hearing loss category. Percentages 
indicate proportion of cases with 
confirmed and/or possibly confirmed 



























Diagnosis confirmed or possibly confirmed No diagnosis confirmed
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31% is broadly comparable to the available literature for this patient 
group4,5 and shows an increased diagnostic utility in comparison 
with previously available genetic testing. In settings where patients 
present with a diverse range of genetically and clinically hetero-
geneous conditions, CES can offer effective diagnostic rates and 
represent a long- term, more cost- effective and suitable choice com-
pared with targeted NGS approaches (i.e., targeted diagnostic gene 
panels).2,11 While a few technical limitations still exist,5 CES clearly 
can increase genetic diagnostic rates in comparison with previously 
available standard genetic testing for hearing loss.
Timely identification of a genetic diagnosis can have strong im-
plications in the context of ear and hearing disorders. Firstly, the 
early confirmation or exclusion of syndromic conditions can inform 
future diagnostic workup and promote more cost- effective use of 
healthcare resources.12 Compared with standard of care, CES can 
reduce unnecessary diagnostic interventions through the increased 
identification of molecular diagnoses. It has been shown that, while 
CES incurs additional costs, it can be cost- effective in hearing loss 
due to the increase in diagnostic yield.13 Results can streamline di-
agnostic interventions and treatment options. In a hearing loss con-
text, timing of testing can be key in assessing the clinical utility and 
consequent economic impact of genomic sequencing. It is possible 
that redefining the hierarchy of diagnostic testing battery is required 
to balance the number of interventions needed to obtain an ade-
quate amount of clinical data to be used for clinical interpretation 
of genomic sequencing variants. Further health- economics research 
should be conducted to validate this across different payer health-
care systems.
Secondly, the increasing integration of genomic, clinical and 
laboratory data, including outcomes, can be used to develop prog-
nostic models that inform management decision- making. Although 
it is highly unlikely that genomic diagnosis would preclude cochlear 
implantation or any other type of hearing habilitation or rehabili-
tation, molecular diagnosis can facilitate the identification of pa-
tients in need of targeted rehabilitation due to a predicted risk of 
poor performance. There is a growing body of evidence on the use 
of genetic diagnosis for prediction of cochlear implantation out-
comes,14,15 and in SNHL associated with enlarged vestibular aque-
ducts, the presence or absence of key genomic variants may also be 
of prognostic value for hearing loss severity and/or progression.16 
Early genetic diagnosis can inform clinical care teams of an in-
creased risk of hearing loss progression, warranting closer surveil-
lance that prompts early consideration of cochlear implantation. 
Finally, genomic findings are clinically relevant to family members, 
permitting confirmatory testing and accurate counselling about re-
productive risks and choices.
While this study is limited by a relatively small sample size and 
its retrospective design, it confirms the current diagnostic capability 
of CES and offers some insights into real- life, clinical use of genomic 
sequencing. It highlights the heterogeneity in patients currently re-
ferred to NHS Genomic Medicine services. It is also important to 
note that the diagnostic capability of CES is enriched by good phe-
notyping. Analysis of CES data is clinically driven and thus requires 
detailed phenotyping. The need for phenotype reassessment in 
some patients denotes the importance of pursuing further integra-
tion between clinical and genomic services. Multidisciplinary team 
evaluation by ENT surgeons, audiologists and clinical geneticists can 
enhance the quality of phenotype data and reduce referral delays 
between specialities. Consequently, this can facilitate interpretation 
of CES data, shorten turnaround times and expedite molecular diag-
nosis, allowing for a timely optimisation of individualised hearing and 
disease surveillance.
In summary, CES is a powerful tool in the diagnostic investigation 
of patients with ear and hearing disorders, with direct implications 
for patient care. Due to the prevalence and diversity of genetic ae-
tiologies for congenital ear anomalies and hearing impairment, in-
corporating early molecular diagnosis into existing comprehensive 
multidisciplinary care has the potential to improve both patient 
counselling (regarding recurrence risks and disease prognostication) 
and, in turn, clinical outcomes.
ACKNOWLEDG EMENTS
LPMR was sponsored by Mexico’s National Council of Science and 
Technology, (CONACyT)- 392996. HS is supported by Peter Mount 
award (Manchester University NHS Foundation Trust)- G70658; 
Data Driven Award (Manchester University NHS Foundation 
Trust)- NH_SY_020419 and the Royal College of Surgeons. WGN is 
supported by Manchester NIHR BRC IS- BRC- 1215- 20007. GCB is 
supported by the Wellcome Trust (200990/Z/16/Z, Transforming 
Genetic Medicine Initiative). The authors would like to thank 
Jonathan Edgerley, clinical scientist at the Manchester Centre for 
Genomic Medicine, for his support and assistance with data collec-
tion for this study.
CONFLIC T OF INTERE S T
We also hereby declare that none of the authors have any disclo-
sures to share, nor any conflict of interest.
AUTHOR CONTRIBUTIONS
LPMR, EMMBW, IAB and GCMB designed and coordinated the 
study. LPMR, EMMBW, CK and AT collected the data. LPMR, 
EMMBW, HS, IAB and GCMB analysed and interpreted the data. 
SSB contributed to bioinformatics and maintenance of bioinformat-
ics pipeline. AT contributed to virtual gene panel algorithm and de-
velopment of clinical exome web referral system. LD contributed to 
exome sequencing experiments. CK, RW, EMMBW, SSB, CC, SB, AS, 
CF, JHMcD, TAB, JCS, SD, KC, WGN and GCMB contributed to ge-
netic and/or phenotypic data. LPMR, EMMBW, HS, IAB and GCMB 
wrote the manuscript. All the authors revised the manuscript for im-
portant intellectual content and approved the final version.
E THIC AL APPROVAL
This study was conducted as an audit of results and performance 
following changes to the standard procedures for the referral and 
analysis of the existing Clinical Exome service. Through the clinical 
exome- informed consent process, patients consented to having their 
     |  5MOLINA- RAMÍREZ Et AL.
sample, genomic data and clinical information shared internally and 
with other researchers through scientific publications, controlled- 
access databases and open- access databases.
DATA AVAIL ABILIT Y S TATEMENT
The data that support the findings of this study are available on re-
quest from the corresponding author. The data are not publicly avail-
able due to privacy or ethical restrictions.
Leslie P. Molina- Ramírez1,2





















1Division of Evolution and Genomic Sciences, Manchester 
Academic Health Science Centre, Faculty of Biology, Medicine 
and Health, School of Biological Sciences, University of 
Manchester, Manchester, UK
2Manchester Centre for Genomic Medicine, St. Mary's Hospital, 
Manchester University NHS Foundation Trust, Manchester, UK
3Paediatric ENT Department, Manchester Academic Health 
Science Centre, Royal Manchester Children's Hospital, 
Manchester University Hospitals NHS Foundation Trust, 
Manchester, UK
4Division of Infection, Immunity and Respiratory Medicine, 
Faculty of Biology, Medicine, Health University of Manchester, 
Manchester, UK
Correspondence
Iain A Bruce, Manchester Academic Health Science 
Centre, Royal Manchester Children's Hospital, Manchester 
University Hospitals NHS Foundation Trust, Oxford Road 
Manchester, M13 9WL, UK.
Email: iain.bruce@manchester.ac.uk
Leslie P. Molina- Ramírez and Emma Mm Burkitt- Wright have co- 
first authorship. 
ORCID
Leslie P. Molina- Ramírez  https://orcid.
org/0000-0001-7573-6846 
Haroon Saeed  https://orcid.org/0000-0002-2624-0518 
John H. McDermott  https://orcid.org/0000-0002-5220-8837 
Jill Clayton- Smith  https://orcid.org/0000-0002-9602-2321 
Sofia Douzgou  https://orcid.org/0000-0001-8890-7544 
Tracy A. Briggs  https://orcid.org/0000-0001-5208-2691 
Siddharth Banka  https://orcid.org/0000-0002-8527-2210 
William G. Newman  https://orcid.org/0000-0002-6382-4678 
Iain A. Bruce  https://orcid.org/0000-0003-0831-4760 
Graeme C. Black  https://orcid.org/0000-0001-8727-6592 
R E FE R E N C E S
 1. Luquetti DV, Heike CL, Hing AV, Cunningham ML, Cox TC. Microtia: 
epidemiology and genetics. Am J Med Genet A. 2012;158A(1):12
4- 139. https://doi.org/10.1002/ajmg.a.34352
 2. Wright CF, FitzPatrick DR, Firth HV. Paediatric genomics: diagnos-
ing rare disease in children. Nat Rev Genet. 2018;19(5):253- 268.
 3. Sommen M, Wuyts W, Van Camp G. Molecular diagnostics 
for hereditary hearing loss in children. Expert Rev Mol Diagn. 
2017;17(8):751- 760.
 4. Zazo Seco C, Wesdorp M, Feenstra I, et al. The diagnostic yield of 
whole- exome sequencing targeting a gene panel for hearing im-
pairment in the Netherlands. Eur J Hum Genet. 2017;25(3):308- 314. 
https://doi.org/10.1038/ejhg.2016.182
 5. Sheppard S, Biswas S, Li MH, et al. Utility and limitations of exome 
sequencing as a genetic diagnostic tool for children with hearing 
loss. Genet Med. 2018;20(12):1663- 1676. https://doi.org/10.1038/
s4143 6- 018- 0004- x
 6. Iglesias A, Anyane- Yeboa K, Wynn J, et al. The usefulness of 
whole- exome sequencing in routine clinical practice. Genet Med. 
2014;16(12):922- 931.
 7. Molina- Ramírez LP, Kyle C, Ellingford JM, et al. Personalised vir-
tual gene panels reduce interpretation workload and maintain di-
agnostic rates of proband- only clinical exome sequencing for rare 
disorders. J Med Genet. 2021. http://dx.doi.org/10.1136/jmedg 
enet- 2020- 107303
 8. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the 
interpretation of sequence variants: a joint consensus recom-
mendation of the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology. Genet Med. 
2015;17(5):405- 423.
 9. Caulfield M, Davies J, Dennys M, et al. The national genomics re-
search and healthcare knowledgebase. 2019.
 10. Sloan- Heggen CM, Bierer AO, Shearer AE, et al. Comprehensive ge-
netic testing in the clinical evaluation of 1119 patients with hearing 
loss. Hum Genet. 2016;135(4):441- 450. https://doi.org/10.1007/
s0043 9- 016- 1648- 8
 11. Lionel AC, Costain G, Monfared N, et al. Improved diagnostic yield 
compared with targeted gene sequencing panels suggests a role for 
whole- genome sequencing as a first- tier genetic test. Genet Med. 
2018;20(4):435- 443.
 12. Stark Z, Schofield D, Martyn M, et al. Does genomic sequencing 
early in the diagnostic trajectory make a difference? A follow- up 
study of clinical outcomes and cost- effectiveness. Genet Med. 
2019;21(1):173- 180.
6  |     MOLINA- RAMÍREZ Et AL.
 13. Downie L, Amor DJ, Halliday J, Lewis S, Martyn M, Goranitis I. 
Exome sequencing for isolated congenital hearing loss: a cost- 
effectiveness analysis. Laryngoscope. 2021;131(7):E2371- E2377. 
https://doi.org/10.1002/lary.29356
 14. Yoshimura H, Moteki H, Nishio S, Miyajima H, Miyagawa M, 
Usami S. Genetic testing has the potential to impact hearing 
preservation following cochlear implantation. Acta Otolaryngol. 
2020;140(6):438- 444.
 15. Shearer AE, Eppsteiner RW, Frees K, et al. Genetic variants in 
the peripheral auditory system significantly affect adult cochlear 
implant performance. Hear Res. 2017;348:138- 142. https://doi.
org/10.1016/j.heares.2017.02.008
 16. Chao JR, Chattaraj P, Munjal T, et al. SLC26A4- linked CEVA haplo-
type correlates with phenotype in patients with enlargement of the 
vestibular aqueduct. BMC Med Genet. 2019;20(1):118.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Molina- Ramírez LP, Burkitt- Wright 
EMM, Saeed H, et al. The diagnostic utility of clinical exome 
sequencing in 60 patients with hearing loss disorders: A 
single- institution experience. Clin Otolaryngol. 2021;00:1– 6. 
https://doi.org/10.1111/coa.13826
